Baxter International Inc. (BAX): Today's Featured Health Services Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Baxter International ( BAX) pushed the Health Services industry lower today making it today's featured Health Services laggard. The industry as a whole was unchanged today. By the end of trading, Baxter International fell $0.82 (-1.2%) to $67.35 on average volume. Throughout the day, 3,797,627 shares of Baxter International exchanged hands as compared to its average daily volume of 3,573,000 shares. The stock ranged in price between $67.04-$68.18 after having opened the day at $68.18 as compared to the previous trading day's close of $68.17. Other companies within the Health Services industry that declined today were: Vision-Sciences Inc (DE ( VSCI), down 10.8%, Thermogenesis Corporation ( KOOL), down 10.4%, Health Insurance Innovations ( HIIQ), down 9.0% and AcelRx Pharmaceuticals ( ACRX), down 7.2%.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $37.1 billion and is part of the health care sector. The company has a P/E ratio of 17.3, below the S&P 500 P/E ratio of 17.7. Shares are up 2.3% year to date as of the close of trading on Monday. Currently there are 5 analysts that rate Baxter International a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the positive front, EnteroMedics ( ETRM), up 63.5%, Unilife Corporation ( UNIS), up 16.6%, Baxano Surgical ( BAXS), up 13.5% and Retractable Technologies ( RVP), up 11.1% , were all gainers within the health services industry with Boston Scientific ( BSX) being today's featured health services industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing